Validating proprietary healthcare technology —
securing a €10 million strategic investment
An evergreen investment fund needed absolute certainty regarding the custom medical platform at the heart of an acquisition target’s operational model. We audited the technology’s maturity, regulatory compliance, and market differentiation to give the buyer the confidence required to close the deal.
A global evergreen investment firm supporting long-term visionary scale-ups
The client is a worldwide evergreen investment company backed by a prominent family office. They specialize in supporting companies with the potential to scale globally and become best-in-class players within their respective sectors.
Their investment philosophy relies on matching the shareholder’s timing with the entrepreneur’s vision, operating with an unlimited time horizon. This approach allows them to leverage their extensive global network and deep entrepreneurial spirit to build lasting, sustainable value.
A highly regulated, proprietary platform holding the keys to operational scale
The target company, a new-generation network of medical centers, operates a fully in-house software platform managing critical medical workflows, patient data, and appointment logistics. As technology and data are the core engines of their operational model, our client required a definitive perspective before proceeding with a major capital investment.
The assessment needed to validate the platform’s true differentiators against market equivalents and confirm its long-term viability. Furthermore, the technology faced intense regulatory scrutiny, requiring strict compliance with Health Data Hosting (HDS) standards while supporting diverse user profiles across a distributed network of clinics.
It was imperative to untangle the complexities of their external integrations, from national health insurance systems to secure practitioner networks. We had to ensure the underlying organizational maturity could support the platform’s future growth without introducing systemic risk.
“Supporting the development of a player in a highly regulated sector requires an ambition for digital innovation around better data exploitation, but equally, organizational innovation.”
Three phases, one accountable owner
We structured the engagement to move from rigorous technical auditing to actionable strategic planning, ensuring every deliverable served the investment thesis.
What changed and how we measured it
The technological due diligence provided the concrete assurances required to move the transaction forward safely.
Investment Secured: The client confidently validated the investment thesis, successfully entering the target company's capital with a major funding round.
Operational Trajectory: The medical network gained a clearly defined, highly optimized trajectory for their daily operations, entirely powered by their proprietary platform.
Product Vision: The target secured a clear implementation roadmap transitioning their Tech & Data activities toward an agile, product-oriented approach.
The trust payoff & deliverable
We delivered a comprehensive Technical Due Diligence report alongside a pragmatic 24-month operational roadmap. This gave the investment committee the undeniable, fact-based confidence required to execute the transaction, effectively neutralizing the inherent risks of acquiring a heavily regulated, custom-built medical platform.
By shifting the target’s technological strategy toward a sustainable, product-led vision, we restored alignment between the founders and the incoming investors. Trust was established not just through a successful €10 million transaction, but by securing a shared, scalable blueprint for the future.
Facing a high-stakes acquisition involving proprietary technology?
Access our Alpha self-assessment tool to quantify tech debt and establish a clear baseline today.